原发小血管炎肾损害几种治疗方案的疗效分析被引量：5

下载PDF

导出

摘要目的探讨临床常用方案对原发小血管炎肾损害患者肾损害方面的治疗效果。方法收集近年住院治疗的确诊原发小血管炎合并肾损害的患者85例,根据实际治疗方案的不同分成5组:未用激素和环磷酰胺组,单用标准激素组,甲基泼尼松龙冲击+标准泼尼松方案组,口服泼尼松+环磷酰胺冲击组,甲基泼尼松龙+环磷酰胺双冲击组,对比分析各组患者治疗前后血尿、蛋白尿、血尿素氮和肌酐水平的改变。结果①5组患者治疗后的组间相比,不论是蛋白尿、血尿,还是血肌酐水平,差异均有统计学意义(P<0.05),联合使用激素和环磷酰胺的患者血尿、蛋白尿程度和血肌酐水平明显下降;②治疗前后组内自身对照分析,单使用激素组,仅血尿有改善(P<0.05),口服泼尼松+环磷酰胺冲击组,血尿和蛋白尿显著减轻(P<0.05);甲基泼尼松龙+环磷酰胺双冲击组,血尿和蛋白尿显著减轻(P<0.05)。结论激素联合环磷酰胺方案对具有更好的肾脏损害治疗效果,优于单用激素,而不用激素和免疫抑抑制剂的方案,疗效欠佳。

作者薛超卜昆鹏廖蕴华

机构地区广西医科大学第一附属医院肾内科

出处《中国老年学杂志》 CAS CSCD 北大核心 2011年第18期3463-3465,共3页 Chinese Journal of Gerontology

基金广西医科大学校博士启动基金(308019) 广西科学基金(桂科青0728060) 广西卫生厅自筹基金(z200788)

关键词 ANCA相关性小血管炎激素环磷酰胺治疗

分类号 R446.8 [医药卫生—诊断学]

引文网络
相关文献

参考文献11

1Holle JU, Wieczorek S, Gross WL. The future of ANCA-associated vasculitis[J]. Rheum Dis Clin North Am ,2010 ;36 (3) :609-21.
2Jennette JC,Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of An International Consensus Conference[J].Arthritis Rheum, 1994 ;37 (2) :187-92.
3De Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early sys- temic antineutrophil cytoplasmic antibody-associated vasculitis[J]. Arthritis Rheum, 2005 ;52 ( 8 ) : 2461-9.
4Koyama A, Yamagata K, Makino H, et al. A nationwide survey of rapidly progressive glomerulonephritis in Japan:etiology, prognosis and treatment diversity[J]. Clin Exp Nephrol,2009 ; 13 (6) :633-50.
5de Groot K,Harper L,Jayne DR,et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody- associated vasculitis : a randomized trial [J]. Ann Intern Med, 2009 ; 150 (10) :670-80.
6Hu W, Liu C, Xie H, et al. Mycophenolate mofetil versus cyclophospha- mide for inducing remission of ANCA vasculitis with moderate renal in- volvement [J].Nephrol Dial Transplant, 2008 ; 23 ( 4 ) : 1307-12.
7Silva F, Specks U, Kalra S, et al. Mycophenolate mofetil for induction and maintenance of remission in microscopic polyangiitis with mild to moderate renal involvement-a prospective, open-label pilot trial ~ J 3. Clin J Am Soc Nephro1,2010 ;5 ( 3 ) :445-53.
8Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA -associated vasculitis[J]. N Engl J Med, 2010 ; 363 ( 3 ) : 221-32.
9Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyelophospha- mide in ANCA-assoeiated renal vaseulitis [J].N Engl J Med, 2010 ; 363 (3) :211-20.
10Booth A, Harper L, Hammad T,et al. Prospective study of TNF alpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis[J].J Am Soc Nephrol,2004 ; 15 ( 3 ) :717-21.